Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered
Human content, AI powered search.

Latest Stories

Pharmacies asked to quarantine and return Accord's Digoxin BP tablets 250mg

pharmacy.biz Staff
By pharmacy.biz StaffAug 03, 2020
pharmacy.biz Staff
See Full Bio

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 drug alert for Accord's Digoxin BP tablets 250mg.

Digoxin is prescription only medicine and is indicated for the treatment of congestive cardiac failure.

"Accord-UK Ltd has informed us of an issue related to decommissioning of a specific batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D code, the status of the packs may report as 'export', the MHRA said in a statement.

The regulator has advised that although there is no risk to product quality, any remaining stock should be quarantined and returned.

Related News

B&S Group has mourned the death of Ketan Shah in the Air India plane crash in India last week
News

B&S Group mourns the death of Ketan Shah in Air India crash

NHS app to boost clinical trials
News

Government to use NHS app to boost clinical trials

More For You

Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc